{"id":11362,"date":"2026-11-21T08:16:05","date_gmt":"2026-11-21T13:16:05","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11362"},"modified":"2026-11-21T08:17:18","modified_gmt":"2026-11-21T13:17:18","slug":"medicure-gains-big-double-digits-coming-soon","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/medicure-gains-big-double-digits-coming-soon\/","title":{"rendered":"Medicure Gains 3.51% to $3.83 and Double Digits Coming Soon"},"content":{"rendered":"\n<div style=\"width:100%; max-width:650px; margin:0 auto; padding:0 10px; box-sizing:border-box; font-family:Arial,Helvetica,sans-serif; font-size:14px; line-height:1.65; color:#333333; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; text-size-adjust:100%;\">\n\n<p style=\"margin:0 0 18px; padding:0;\">\n<strong>Medicure (TSXV: MPH)<\/strong> <span style=\"color:#27ae60;\"><strong>gained by 3.51%<\/strong><\/span> on Friday to <strong>$3.83 per share<\/strong>!\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\n<strong>MPH<\/strong> <span style=\"color:#27ae60;\"><strong>rose<\/strong><\/span> to <strong>$10.67 per share<\/strong> one decade ago in 2016 and <span style=\"color:#2980b9;\"><strong>averaged<\/strong><\/span> a price of <strong>$7.86 per share<\/strong> over the following 24-month time period back when it had <strong>15.88 million shares outstanding<\/strong>.\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\nToday, <strong>MPH<\/strong> has only <strong>10.436 million shares outstanding<\/strong> and a market cap of <strong>US$27.86 million<\/strong>.\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\n<strong>MPH<\/strong> will <span style=\"color:#27ae60;\"><strong>earn<\/strong><\/span> a <strong>Priority Review Voucher<\/strong> after it <span style=\"color:#27ae60;\"><strong>receives<\/strong><\/span> <strong>FDA Approval<\/strong> for <strong>MC-1<\/strong> that it will sell to a <span style=\"color:#2980b9;\"><strong>major<\/strong><\/span> <strong>pharmaceutical company<\/strong> for an estimated <strong>US$205 million<\/strong>.\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\n<strong>MPH<\/strong> will <span style=\"color:#27ae60;\"><strong>break out<\/strong><\/span> past <strong>$10.67 per share<\/strong> with <span style=\"color:#2980b9;\"><strong>ease<\/strong><\/span> in the upcoming weeks and <span style=\"color:#27ae60;\"><strong>surpass<\/strong><\/span> <strong>$20 per share<\/strong> long before the <strong>Phase 3 trial results<\/strong> are released in <strong>September 2027<\/strong>.\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\n<strong>MC-1<\/strong> really works to <span style=\"color:#2980b9;\"><strong>cure<\/strong><\/span> <strong>PNPO deficiency<\/strong>. When we say ask the <span style=\"color:#27ae60;\"><strong>most advanced<\/strong><\/span> <strong>AI models<\/strong> like <strong>Claude<\/strong> about it, we are being <span style=\"color:#2980b9;\"><strong>sarcastic<\/strong><\/span>, but still, it is okay to <span style=\"color:#2980b9;\"><strong>use<\/strong><\/span> them as part of your research. <strong>Anthropic (ANT) investors<\/strong> who <span style=\"color:#27ae60;\"><strong>buy<\/strong><\/span> today near the top will <span style=\"color:#e74c3c;\"><strong>lose all their money<\/strong><\/span> as <strong>Medicure (TSXV: MPH) investors<\/strong> make <span style=\"color:#27ae60;\"><strong>massive profits<\/strong><\/span>. <strong>MPH<\/strong> will be <strong>$30 per share<\/strong> by this time next year.\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\n<strong>Be sure you tell all of your friends and family members about Medicure during the Thanksgiving and Christmas holidays.<\/strong> In January we should begin to <span style=\"color:#2980b9;\"><strong>actively spread<\/strong><\/span> <strong>word<\/strong> about <strong>Medicure<\/strong> to <strong>biotech investors<\/strong> on social media. Because it is listed on the <strong>TSX Venture Exchange<\/strong>, <span style=\"color:#e74c3c;\"><strong>no<\/strong><\/span> <strong>biotech investors<\/strong> know that <strong>Medicure<\/strong> even exists. <strong>U.S. listed biotech stocks<\/strong> in <strong>Phase 3 trials<\/strong> typically <span style=\"color:#2980b9;\"><strong>start<\/strong><\/span> at a <span style=\"color:#27ae60;\"><strong>US$100 million<\/strong><\/span> <strong>market cap<\/strong> in a <span style=\"color:#e74c3c;\"><strong>worst-case<\/strong><\/span> <strong>scenario<\/strong> and those companies are always <span style=\"color:#e74c3c;\"><strong>burning<\/strong><\/span> massive amounts of cash and <span style=\"color:#e74c3c;\"><strong>don&#8217;t<\/strong><\/span> have <strong>Rare Pediatric Disease Designations<\/strong> that will earn them a <strong>Priority Review Voucher<\/strong>.\n<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">\nThe <strong>FDA&#8217;s Rare Pediatric Disease Priority Review Voucher (PRV)<\/strong> program is authorized through <strong>September 30, 2029<\/strong>, so <strong>Medicure<\/strong> will be <span style=\"color:#27ae60;\"><strong>earning<\/strong><\/span> it <span style=\"color:#2980b9;\"><strong>well before<\/strong><\/span> the <span style=\"color:#e74c3c;\"><strong>cutoff<\/strong><\/span> date. The <strong>PRV<\/strong> <span style=\"color:#e74c3c;\"><strong>doesn&#8217;t expire<\/strong><\/span> so there will be <span style=\"color:#2980b9;\"><strong>countless major<\/strong><\/span> <strong>pharmaceutical companies<\/strong> <span style=\"color:#27ae60;\"><strong>eager to buy<\/strong><\/span> the <strong>PRV<\/strong> from <strong>Medicure<\/strong> for an estimated <span style=\"color:#27ae60;\"><strong>US$205 million<\/strong><\/span>.\n<\/p>\n\n<p style=\"margin:22px 0 20px; padding:0; text-align:center;\">\n<img decoding=\"async\" src=\"https:\/\/www.inflation.us\/news\/wp-content\/uploads\/2026\/11\/mph383.jpg\" alt=\"Medicure MPH stock chart\" width=\"600\" height=\"311\" style=\"display:block; width:100%; max-width:600px; height:auto; margin:0 auto; border:0;\" \/>\n<\/p>\n\n<p style=\"margin:18px 0 0; padding:12px 0 0; border-top:1px solid #dddddd; font-size:10px; line-height:1.5; color:#777777;\">\n<em>Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA&#8217;s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.<\/em>\n<\/p>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Medicure (TSXV: MPH) gained by 3.51% on Friday to $3.83 per share! MPH rose to $10.67 per share one decade ago in 2016 and averaged a price of $7.86 per share over the following 24-month time period back when it had 15.88 million shares outstanding. Today, MPH has only 10.436 million shares outstanding and a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11364,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[426,365,414],"class_list":["post-11362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-ant","tag-biotech","tag-mph"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11362"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11362\/revisions"}],"predecessor-version":[{"id":11365,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11362\/revisions\/11365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11364"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}